12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

Oasmia, Abbott deal

Abbott and Oasmia amended a 2009 deal to give Abbott exclusive commercialization rights to Oasmia's canine oncology compounds Paccal Vet and Doxophos Vet. The deal...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >